Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2012-01-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 528
- Registration Number
- NCT01000805
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden
A Weight Loss Study in Overweight Men and Women
- Conditions
- Obesity
- Interventions
- Drug: LY377604Drug: Placebo sibutramineDrug: Placebo MetoprololDrug: SibutramineDrug: MetoprololDrug: Placebo LY377604
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2011-06-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 343
- Registration Number
- NCT00993421
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States
A Study of LY573636-sodium in Patients With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: LY573636-sodium
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 43
- Registration Number
- NCT00992225
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Temple, Texas, United States
A Study of Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT00988858
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan
A Study on the Effect of 2 Pen Devices on HbA1c
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 263
- Registration Number
- NCT00985712
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wuppertal, Germany
A Study of Patients With Major Depressive Disorder and Residual Apathy
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2011-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 483
- Registration Number
- NCT00985504
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1093
- Registration Number
- NCT00981058
- Locations
- 🇬🇧
ImClone Investigational Site, Preston, United Kingdom
🇭🇷ImClone Investigational site, Zagreb, Croatia
Study in Adolescents With Schizophrenia or Bipolar Disorder
- Conditions
- Bipolar I DisorderSchizophrenia
- Interventions
- Drug: OlanzapineBehavioral: Intense behavioral weight interventionBehavioral: Standard behavioral weight intervention
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 203
- Registration Number
- NCT00982020
- Locations
- 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saratov, Russian Federation
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 633
- Registration Number
- NCT00982111
- Locations
- 🇪🇸
Imclone Investigational Site, Sevilla, Andalucia, Spain
🇬🇧ImClone Investigational Site, Preston, United Kingdom
A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Lispro Mix 50/50
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 135
- Registration Number
- NCT00971997
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yamanashi, Japan